“…In the past decades, for mimicking the endogenous enzymes and overcoming their drawbacks (easily affected antioxidative properties by redox microenvironments and pH changes, and specific reactive nitrogen and oxygen species (RNOS) scavenging activity), artificial enzymes (also termed as nanozymes) have aroused great interest and enthusiasm in oxidative stress treatment due to their high stability and versatile enzyme simulation selectivity. − Until now, various nanozymes, including metal nanoparticles such as platinum, metal oxides such as CeO 2 , , Mn 3 O 4 , , and Fe 3 O 4 , transition metal dichalcogenides, , prussian blue nanoparticles, ,, quantum dots, , single atom catalysts, and metal-phenolic nanozymes, , have been developed for antioxidative applications. For example, the cascade nanozymes have exhibited superior therapeutic efficacy for in vivo inflammatory treatment. − However, the application of artificial enzymes in blood purification is almost nonexistent, which could be ascribed to the following reasons: (1) most reported nanozymes are single components, which hardly prevent oxidative damage completely because the multiple pathways that produce ROS are activated for the CKD patients with maintenance blood purification; , (2) determining the kinds and accurate dosages of nanozymes is complicated due to the inter-patient variability and varied disease states for these patients; (3) once the antioxidative nanozymes with poor biocompatibility enter the blood directly, they will cause blood clots and blockage of blood vessels. − Therefore, an ideal strategy to achieve the oxidative stress treatment in the extracorporeal circulation of blood purification should meet these two requirements: (1) the developed antioxidative nanozymes should effectively scavenge multiple ROS, and (2) the antioxidative process should be temporary and localized, which could prevent the nanozymes going into the bloodstream to induce some potential side effects.…”